The present invention relates to salts and compositions for use in the treatment of ischaemic stroke reperfusion (IR) injury. In particular, the present invention relates to a salt of formula (I) for use in treating or preventing ischaemic stroke reperfusion injury, wherein X, Y, n, m, Z, A and B are as defined herein.

The present invention relates to salts and compositions for use in the treatment of ischaemic stroke reperfusion (IR) injury. In particular, the present invention relates to a salt of formula (I) for use in treating or preventing ischaemic stroke reperfusion injury, wherein X, Y, n, m, Z, A and B are as defined herein.

A smokeless tobacco product is provided that includes a tobacco material in the form of a tobacco extract, a particulate tobacco material, or a combination thereof. In some embodiments, the smokeless tobacco product is substantially translucent. Methods for making and using the smokeless tobacco product are also provided. The smokeless tobacco product can include isomalt, maltitol syrup, particulate tobacco, and a translucent tobacco extract prepared by ultrafiltration.

A smokeless tobacco product is provided that includes a tobacco material in the form of a tobacco extract, a particulate tobacco material, or a combination thereof. In some embodiments, the smokeless tobacco product is substantially translucent. Methods for making and using the smokeless tobacco product are also provided. The smokeless tobacco product can include isomalt, maltitol syrup, particulate tobacco, and a translucent tobacco extract prepared by ultrafiltration.

A nutritional composition comprises (a) one to a plurality of physiologically acceptable calcium salts and/or chelates and (b) one or more phosphorus-containing components, such as phosphate salts, and/or phosphorus-rescuing components, such as phytase. The composition is useful for phosphorus-sparing calcium supplementation of the diet of a human subject, and for treatment of a low bone density condition in a human subject in need thereof.

A nutritional composition comprises (a) one to a plurality of physiologically acceptable calcium salts and/or chelates and (b) one or more phosphorus-containing components, such as phosphate salts, and/or phosphorus-rescuing components, such as phytase. The composition is useful for phosphorus-sparing calcium supplementation of the diet of a human subject, and for treatment of a low bone density condition in a human subject in need thereof.

A composition, usable for removing a biofilm and necrotic or infected tissues from skin lesions and lesions of the oral cavity, comprises methanesulfonic acid 99.0% and a proton acceptor. The proton acceptor is selected from the group consisting of: anhydrous sodium carbonate, 5 -amino-2-mercaptobenzimidazole, ethylenediaminetetraacetic acid tetrasodium salt, sodium gluconate, sodium tartrate dihydrate, 2-mercapto-5-benzimidazole sodium sulfonate, dimethyl sulfoxide, polyethylene glycol 400, polyethylene glycol 600, silicon dioxide, tetraethoxysilane, and mixtures thereof. The aforesaid composition can be prepared in the form of a solution, gel or cream.

A composition, usable for removing a biofilm and necrotic or infected tissues from skin lesions and lesions of the oral cavity, comprises methanesulfonic acid 99.0% and a proton acceptor. The proton acceptor is selected from the group consisting of: anhydrous sodium carbonate, 5 -amino-2-mercaptobenzimidazole, ethylenediaminetetraacetic acid tetrasodium salt, sodium gluconate, sodium tartrate dihydrate, 2-mercapto-5-benzimidazole sodium sulfonate, dimethyl sulfoxide, polyethylene glycol 400, polyethylene glycol 600, silicon dioxide, tetraethoxysilane, and mixtures thereof. The aforesaid composition can be prepared in the form of a solution, gel or cream.

A mucoadhesive composition including denture adhesive composition comprising: (i) 10 to about 75 wt. % of a maleic acid or anhydride copolymer; (ii) 10 to about 50 wt. % of a cellulose ether; (iii) 0.1 to 10 wt. % of a crosslinked polyvinyl pyrrolidone that is swellable but not soluble in water; and (iv) 30 to 70 wt. % of an orally acceptable carrier based on the total weight of the composition. Also disclosed is a method of use thereof and a process lot preparing the same.

A mucoadhesive composition including denture adhesive composition comprising: (i) 10 to about 75 wt. % of a maleic acid or anhydride copolymer; (ii) 10 to about 50 wt. % of a cellulose ether; (iii) 0.1 to 10 wt. % of a crosslinked polyvinyl pyrrolidone that is swellable but not soluble in water; and (iv) 30 to 70 wt. % of an orally acceptable carrier based on the total weight of the composition. Also disclosed is a method of use thereof and a process lot preparing the same.